MIRA Competitors
| MIRA Stock | 1.19 0.02 1.65% |
MIRA Pharmaceuticals vs Q32 Bio Correlation
Very good diversification
The correlation between MIRA Pharmaceuticals Common and QTTB is -0.49 (i.e., Very good diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding MIRA Pharmaceuticals Common and QTTB in the same portfolio, assuming nothing else is changed.
Moving together with MIRA Stock
Moving against MIRA Stock
| 0.84 | PFE | Pfizer Inc CDR | PairCorr |
| 0.82 | PFE | Pfizer Inc | PairCorr |
| 0.8 | H6D | Haleon PLC Earnings Call This Week | PairCorr |
| 0.78 | AMG | Amgen Inc | PairCorr |
| 0.74 | ELVN | Enliven Therapeutics | PairCorr |
MIRA Pharmaceuticals Competition Correlation Matrix
Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between MIRA Pharmaceuticals and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of MIRA and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of MIRA Pharmaceuticals does not affect the price movement of the other competitor.
High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between MIRA Stock performing well and MIRA Pharmaceuticals Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze MIRA Pharmaceuticals' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| MYO | 3.58 | (0.23) | 0.00 | (0.04) | 0.00 | 8.79 | 21.89 | |||
| TLPH | 2.83 | (0.60) | 0.00 | 1.10 | 0.00 | 5.60 | 22.45 | |||
| APUS | 7.43 | (0.95) | 0.00 | (0.21) | 0.00 | 14.36 | 59.03 | |||
| POCI | 2.28 | (0.08) | 0.00 | (0.22) | 0.00 | 4.39 | 19.32 | |||
| MLSS | 2.99 | (0.32) | 0.00 | (0.62) | 0.00 | 7.14 | 23.59 | |||
| IGC | 2.72 | (0.47) | 0.00 | (0.69) | 0.00 | 6.06 | 25.10 | |||
| MODD | 4.50 | 0.11 | 0.00 | (11.79) | 6.35 | 10.00 | 38.80 | |||
| ANTX | 2.55 | (0.09) | 0.00 | (0.22) | 0.00 | 5.56 | 32.31 | |||
| NNVC | 3.88 | (0.49) | 0.00 | (0.27) | 0.00 | 7.53 | 24.18 | |||
| QTTB | 5.14 | 1.65 | 0.27 | (1.46) | 4.44 | 9.56 | 85.16 |
Cross Equities Net Income Analysis
Compare MIRA Pharmaceuticals and related stocks such as Myomo Inc, Talphera, and Apimeds Pharmaceuticals Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MYO | (3.5 M) | (3.5 M) | (3.5 M) | (3.5 M) | (3.5 M) | (4.5 M) | (3.6 M) | (12.1 M) | (10.3 M) | (10.7 M) | (11.6 M) | (10.4 M) | (10.7 M) | (8.1 M) | (6.2 M) | (5.6 M) | (5.8 M) |
| TLPH | (9.6 M) | (20.1 M) | (33.4 M) | (23.4 M) | (33.4 M) | (24.4 M) | (43.2 M) | (51.5 M) | (47.1 M) | (53.2 M) | (40.4 M) | (35.1 M) | 42.5 M | (18.4 M) | (13 M) | (15 M) | (15.7 M) |
| APUS | (1 M) | (1 M) | (1 M) | (1 M) | (1 M) | (1 M) | (1 M) | (1 M) | (1 M) | (1 M) | (1 M) | (1 M) | (668.7 K) | (777.7 K) | (1.4 M) | (1.3 M) | (1.3 M) |
| POCI | 200 K | 961 K | (1.8 M) | (1.2 M) | (1.2 M) | (1 M) | (1 M) | (351.4 K) | (614.9 K) | (1.4 M) | (102.8 K) | (928.4 K) | (144.6 K) | (3 M) | (5.8 M) | (5.2 M) | (4.9 M) |
| MLSS | (1.9 M) | (1.5 M) | (870.3 K) | 1.5 M | (1.7 M) | (5.5 M) | (5.9 M) | (5.2 M) | (7.4 M) | (7.5 M) | (7.3 M) | (6.8 M) | (8.7 M) | (6.9 M) | (4.7 M) | (4.2 M) | (4.5 M) |
| IGC | 91.9 K | (7.8 M) | (2.3 M) | (3 M) | (4.6 M) | (2.8 M) | (1.9 M) | (1.8 M) | (4.1 M) | (7.3 M) | (8.8 M) | (15 M) | (11.5 M) | (13 M) | (7.1 M) | (6.4 M) | (6.7 M) |
| MODD | (30 K) | (17.5 K) | (20.8 K) | (22.8 K) | (31 K) | (31.1 K) | (106.6 K) | (106.6 K) | (2.5 M) | (5.3 M) | (7.4 M) | (18.6 M) | (13.9 M) | (17.5 M) | (18.8 M) | (16.9 M) | (16.1 M) |
| ANTX | (33.8 M) | (33.8 M) | (33.8 M) | (33.8 M) | (33.8 M) | (33.8 M) | (33.8 M) | (33.8 M) | (33.8 M) | (33.8 M) | (13.6 M) | (21.5 M) | (41.5 M) | (64.7 M) | (51.3 M) | (46.2 M) | (48.5 M) |
| NNVC | (66 K) | (6.2 M) | (8.9 M) | (14.1 M) | (2.2 M) | (10.7 M) | (10.3 M) | (8.6 M) | (8.2 M) | (13.4 M) | (8.8 M) | (8.1 M) | (8.6 M) | (8.3 M) | (9.5 M) | (8.5 M) | (8.9 M) |
| QTTB | (8 M) | (8 M) | (8 M) | (8 M) | (8 M) | (8 M) | (8 M) | (30 M) | (55.6 M) | (103.9 M) | (128.7 M) | (95.8 M) | (42.8 M) | (53.7 M) | (47.7 M) | (43 M) | (45.1 M) |
MIRA Pharmaceuticals and related stocks such as Myomo Inc, Talphera, and Apimeds Pharmaceuticals Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in MIRA Pharmaceuticals financial statement analysis. It represents the amount of money remaining after all of MIRA Pharmaceuticals Common operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.MIRA Pharmaceuticals Competitive Analysis
The better you understand MIRA Pharmaceuticals competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, MIRA Pharmaceuticals' competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across MIRA Pharmaceuticals' competition over several years is one of the best ways to analyze its investment potential.| Better Than Average | Worse Than Peers | View Performance Chart |
MIRA Pharmaceuticals Competition Performance Charts
Five steps to successful analysis of MIRA Pharmaceuticals Competition
MIRA Pharmaceuticals' competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by MIRA Pharmaceuticals in relation to its competition. MIRA Pharmaceuticals' competition analysis typically involves several steps, including:- Identifying the key players in the market: This involves identifying the major competitors of MIRA Pharmaceuticals in the market, both direct and indirect, as well as new entrants and disruptive technologies.
- Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
- Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact MIRA Pharmaceuticals' competitive landscape.
- Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to MIRA Pharmaceuticals, and developing a strategy to address them.
- Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Complement your MIRA Pharmaceuticals position
In addition to having MIRA Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Electronics Thematic Idea Now
Electronics
Companies manufacturing electronic appliances and goods. The Electronics theme has 39 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Electronics Theme or any other thematic opportunities.
| View All Next | Launch |
Check out MIRA Pharmaceuticals Correlation with its peers. You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of MIRA Pharmaceuticals. Expected growth trajectory for MIRA significantly influences the price investors are willing to assign. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive MIRA Pharmaceuticals assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Understanding MIRA Pharmaceuticals requires distinguishing between market price and book value, where the latter reflects MIRA's accounting equity. The concept of intrinsic value - what MIRA Pharmaceuticals' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Market sentiment, economic cycles, and investor behavior can push MIRA Pharmaceuticals' price substantially above or below its fundamental value.
Understanding that MIRA Pharmaceuticals' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether MIRA Pharmaceuticals represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. In contrast, MIRA Pharmaceuticals' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.